Franklyn Ophthalmic Instruments
This article was originally published in The Gray Sheet
Executive SummaryGoing public via proposed offering of 1.25 mil. units at $4 each. The units consist of one share of common stock and one Class A common stock purchase warrant. Each warrant allows the holder to purchase one share of common stock at an exercise price of $5 for a period of five years from the date of the prospectus. The Securities and Exchange Commission filing also covers 200,000 shares of common stock offered by selling stockholders and bridge lender's warrants to purchase 625,000 units, from which the company will not receive proceeds. J. Gregory & Company is underwriting. The Hayward, California-based distributor of non-surgical examination instruments says net proceeds of approximately $4 mil. will go towards the payment of subordinated convertible debentures, redemption of "certain shares" of preferred stock issued by the company to bridge lenders, acquisition of inventory, advertising, promotion, and general working capital purposes.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.